Proactive Investors - Run By Investors For Investors

Redx receives regulatory green light to restart research

It means the company is on track to restart the phase I/II study of its next-generation cancer treatment as planned in the first-half
go sign
The company received the go ahead from the UK’s Medicines and Healthcare products Regulatory Agency

Redx Pharma Plc (LON:REDX) saw its shares jump on Monday after the firm said it had received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.

It means the company is on track to restart the study as planned in the first-half.

RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.

READ: First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

Patients receiving the oral medication will do so at much lower starting doses than originally planned.

“We have learnt a significant amount from the first patient treated with RXC004, and this provides the basis for an optimised RXC004 development plan as well as the confidence to evaluate the clinical potential of RXC004 in cancer patients,” said Natalie Cook, consultant oncologist and principal investigator from the Christie Hospital in Manchester.

Redx chief executive Lisa Anson said she believes the putative treatment has potential used on its own and in combination with standard of care treatments.

“We look forward to working closely with our expert clinical oncology colleagues across the U.K. on this exciting programme,” she added.

In early morning trading, Redx shares were 10.7% higher at 7.75p.

 -- Adds share price --

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
man with erectile dysfunction
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use